WO2005023290A3 - Uses of interferons for the treatment of severe acute respiratory syndrome and other viral infections - Google Patents

Uses of interferons for the treatment of severe acute respiratory syndrome and other viral infections Download PDF

Info

Publication number
WO2005023290A3
WO2005023290A3 PCT/US2004/016201 US2004016201W WO2005023290A3 WO 2005023290 A3 WO2005023290 A3 WO 2005023290A3 US 2004016201 W US2004016201 W US 2004016201W WO 2005023290 A3 WO2005023290 A3 WO 2005023290A3
Authority
WO
WIPO (PCT)
Prior art keywords
subject
treating
acute respiratory
respiratory syndrome
severe acute
Prior art date
Application number
PCT/US2004/016201
Other languages
French (fr)
Other versions
WO2005023290A2 (en
Inventor
Sidney Pestka
Thomas B Lavoie
William A Clark
Original Assignee
Pestka Biomedical Lab Inc
Sidney Pestka
Thomas B Lavoie
William A Clark
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pestka Biomedical Lab Inc, Sidney Pestka, Thomas B Lavoie, William A Clark filed Critical Pestka Biomedical Lab Inc
Priority to EP04776085A priority Critical patent/EP1626734A2/en
Priority to AU2004270102A priority patent/AU2004270102B2/en
Priority to JP2006514937A priority patent/JP2006526022A/en
Priority to CA002526428A priority patent/CA2526428A1/en
Publication of WO2005023290A2 publication Critical patent/WO2005023290A2/en
Priority to IL171991A priority patent/IL171991A0/en
Publication of WO2005023290A3 publication Critical patent/WO2005023290A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Abstract

This invention provides a method of treating a subject afflicted with severe acute respiratory syndrome (SARS), comprising administering to the subject an amount of an interferon polypeptide effective to reduce the concentration of SARS-associated coronavirus particles in the subject, thereby treating the subject. This invention also provides methods of treating a subject infected with certain viruses and methods of reducing a subject’s risk of viral infection, comprising administering to the subject an interferon polypeptide. This invention further provides a method of treating a subject afflicted with influenza or reducing a subject’s risk of influenza virus infection, comprising administering to the subject an interferon polypeptide.
PCT/US2004/016201 2003-05-23 2004-05-21 Uses of interferons for the treatment of severe acute respiratory syndrome and other viral infections WO2005023290A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP04776085A EP1626734A2 (en) 2003-05-23 2004-05-21 Uses of interferons for the treatment of severe acute respiratory syndrome and other viral infections
AU2004270102A AU2004270102B2 (en) 2003-05-23 2004-05-21 Uses of interferons for the treatment of severe acute respiratory syndrome and other viral infections
JP2006514937A JP2006526022A (en) 2003-05-23 2004-05-21 Use of interferon for the treatment of severe acute respiratory syndrome and other viral infections
CA002526428A CA2526428A1 (en) 2003-05-23 2004-05-21 Uses of interferons for the treatment of severe acute respiratory syndrome and other viral infections
IL171991A IL171991A0 (en) 2003-05-23 2005-11-16 Use of an interferon polypeptide in the preparation of a pharmaceutical composition for treating virus infection and a method of treating a virus-infected non human subject

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47313403P 2003-05-23 2003-05-23
US60/473,134 2003-05-23

Publications (2)

Publication Number Publication Date
WO2005023290A2 WO2005023290A2 (en) 2005-03-17
WO2005023290A3 true WO2005023290A3 (en) 2005-12-22

Family

ID=34272431

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/016201 WO2005023290A2 (en) 2003-05-23 2004-05-21 Uses of interferons for the treatment of severe acute respiratory syndrome and other viral infections

Country Status (8)

Country Link
EP (1) EP1626734A2 (en)
JP (1) JP2006526022A (en)
CN (1) CN1832755A (en)
AU (1) AU2004270102B2 (en)
CA (1) CA2526428A1 (en)
IL (1) IL171991A0 (en)
TW (1) TW200509961A (en)
WO (1) WO2005023290A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2292652A2 (en) * 2000-11-03 2011-03-09 Pestka Biomedical Laboratories, Inc. Interferons uses and compositions related thereto
WO2008127711A2 (en) * 2007-04-11 2008-10-23 Pestka Biomedical Laboratories, Inc. Interferons of rhesus and cynomolgus origin and uses thereof
US7625555B2 (en) * 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
PL2544705T3 (en) * 2010-03-12 2017-02-28 Synairgen Research Limited Interferon beta for use in the treatment of lower respiratory tract illness caused by influenza
EP3095444A1 (en) 2015-05-20 2016-11-23 Dublin City University A method of treating peripheral inflammatory disease
EP3118216A1 (en) 2015-07-16 2017-01-18 Nuritas Limited Cellular growth and proliferation promoting peptides, and uses thereof
EP3117830A1 (en) 2015-07-16 2017-01-18 Nuritas Limited Antibacterial peptides, and uses thereof
EP3117831A1 (en) 2015-07-16 2017-01-18 Nuritas Limited Peptides for use in promoting transport of glucose into skeletal muscle
EP3118215A1 (en) 2015-07-16 2017-01-18 Nuritas Limited Anti-inflammatory peptides, and uses thereof
BR112018000660A2 (en) 2015-07-16 2019-05-14 Nuritas Limited anti-inflammatory peptides and their use
WO2018014936A1 (en) 2016-07-18 2018-01-25 Nuritas Limited Topical compositions
WO2018104346A1 (en) 2016-12-05 2018-06-14 Nuritas Limited Compositions comprising peptide wkdeagkplvk
EP3329905A1 (en) 2016-12-05 2018-06-06 Nuritas Limited Topical cosmetic compositions comprising an oligopeptide against anti-aging of the skin
CN108721603B (en) * 2017-04-14 2020-11-13 中国医学科学院基础医学研究所 Use of interferon alpha-1 a for the preparation of a medicament for the treatment of cancer
US11760963B2 (en) 2017-08-23 2023-09-19 KetoneAid Inc. Ketogenic beer and alcoholic beverage mixture containing non-racemic ethyl 3-hydroxybutyrate and/or 1,3 butanediol
EP3783012A1 (en) 2019-08-20 2021-02-24 Nuritas Limited An antimicrobial peptide
MX2022002116A (en) 2019-08-20 2022-03-17 Nuritas Ltd Peptides for treating muscle atrophy.
BR112022005412A2 (en) 2019-09-25 2022-06-21 Univ Dublin Nanoparticulate compositions for gene therapy
MX2022004872A (en) 2019-10-22 2022-05-13 Nuritas Ltd Treatment of non-alcoholic fatty liver disease.
EP3862014A1 (en) 2020-02-07 2021-08-11 Nuritas Limited Treatment of panx1 associated diseases
CN113425832A (en) * 2020-03-23 2021-09-24 杭州先为达生物科技有限公司 Use of interferon lambda in the treatment of infections with novel coronaviruses (2019-nCoV)
US20230119628A1 (en) * 2020-03-27 2023-04-20 Ketoneaid, Inc. Ketone ester as a therapeutic treatment of covid -19 and related viral infections
US20230173096A1 (en) * 2020-05-18 2023-06-08 Northwestern University Targeted antiviral drugs
WO2022079205A1 (en) * 2020-10-15 2022-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of ifn-alpha polypeptides for the treatment of coronavirus infections
WO2023131648A1 (en) 2022-01-05 2023-07-13 Branca Bunus Limited Nanoparticulate compositions for gene therapy
CN114533706B (en) * 2022-02-15 2022-10-14 深圳市利云德生物技术有限公司 Aerosol inhalation preparation for preventing and treating respiratory diseases and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000055324A1 (en) * 1999-03-18 2000-09-21 Zymogenetics, Inc. Murine interferon-alpha named also zcyto13
WO2001024785A2 (en) * 1999-10-01 2001-04-12 Institute Of Molecular And Cell Biology Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases
WO2002015664A2 (en) * 2000-08-23 2002-02-28 The New York Hospital Medical Center Of Queens Methods of preventing or treating west nile virus and other infections
WO2002036627A2 (en) * 2000-11-03 2002-05-10 Pbl Biomedical Laboratories Interferons, uses and compositions related thereto

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000055324A1 (en) * 1999-03-18 2000-09-21 Zymogenetics, Inc. Murine interferon-alpha named also zcyto13
WO2001024785A2 (en) * 1999-10-01 2001-04-12 Institute Of Molecular And Cell Biology Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases
WO2002015664A2 (en) * 2000-08-23 2002-02-28 The New York Hospital Medical Center Of Queens Methods of preventing or treating west nile virus and other infections
WO2002036627A2 (en) * 2000-11-03 2002-05-10 Pbl Biomedical Laboratories Interferons, uses and compositions related thereto

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CINATL J ET AL: "Treatment of SARS with human interferons", LANCET THE, LANCET LIMITED. LONDON, GB, vol. 362, no. 9380, 26 July 2003 (2003-07-26), pages 293 - 294, XP004778208, ISSN: 0140-6736 *
HAAGMANS BART L ET AL: "Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 10, no. 3, March 2004 (2004-03-01), pages 290 - 293, XP002302418, ISSN: 1078-8956 *
HERTZIG T ET AL: "Rapid identification of coronavirus replicase inhibitors using a selectable replicon RNA", JOURNAL OF GENERAL VIROLOGY, SOCIETY FOR GENERAL MICROBIOLOGY, READING, GB, vol. 85, no. Part 6, June 2004 (2004-06-01), pages 1717 - 1725, XP002322066, ISSN: 0022-1317 *
HIGGINS P G ET AL: "INTRANASAL INTERFERON AS PROTECTION AGAINST EXPERIMENTAL RESPIRATORY CORONAVIRUS INFECTION IN VOLUNTEERS", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, DC, US, vol. 24, no. 5, November 1983 (1983-11-01), pages 713 - 715, XP009016436, ISSN: 0066-4804 *
HIGGINS P G ET AL: "THE EFFICACY OF INTRANASAL INTERFERON ALPHA-2A IN RESPIRATORY SYNCYTIAL VIRUS INFECTION IN VOLUNTEERS", ANTIVIRAL RESEARCH, vol. 14, no. 1, 1990, pages 3 - 10, XP002348186, ISSN: 0166-3542 *
KSIAZEK THOMAS G ET AL: "A novel coronavirus associated with severe acute respiratory syndrome", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US, vol. 348, no. 20, 15 May 2003 (2003-05-15), pages 1953 - 1966, XP002339648, ISSN: 1533-4406 *
PEIRIS J S M ET AL: "Coronavirus as a possible cause of severe acute respiratory syndrome", LANCET, LITTLE, BROWM AND CO., BOSTON,, US, vol. 361, no. 9366, 19 April 2003 (2003-04-19), pages 1319 - 1325, XP002295043, ISSN: 0099-5355 *
STROEHER U ET AL: "SEVERE ACUTE RESPIRATORY SYNDROME-RELATED CORONAVIRUS IS INHIBITED BY INTERFERON-ALPHA", JOURNAL OF INFECTIOUS DISEASES, CHICAGO, IL, US, vol. 189, no. 7, 1 April 2004 (2004-04-01), pages 1164 - 1167, XP008037651, ISSN: 0022-1899 *
TURNER R B ET AL: "PREVENTION OF EXPERIMENTAL CORONAVIRUS COLDS WITH INTRANASAL ALPHA-2B INTERFERON", JOURNAL OF INFECTIOUS DISEASES, CHICAGO, IL, US, vol. 154, no. 3, September 1986 (1986-09-01), pages 443 - 447, XP008037795, ISSN: 0022-1899 *

Also Published As

Publication number Publication date
JP2006526022A (en) 2006-11-16
CA2526428A1 (en) 2005-03-17
AU2004270102A1 (en) 2005-03-17
AU2004270102B2 (en) 2009-10-01
CN1832755A (en) 2006-09-13
TW200509961A (en) 2005-03-16
IL171991A0 (en) 2011-08-01
EP1626734A2 (en) 2006-02-22
WO2005023290A2 (en) 2005-03-17

Similar Documents

Publication Publication Date Title
WO2005023290A3 (en) Uses of interferons for the treatment of severe acute respiratory syndrome and other viral infections
MY141003A (en) Materials and methods for treating viral infections with a cysteamine compound
EA200201263A1 (en) METHODS OF TREATING INFECTIONS, CAUSED BY THE HEPATITIS DELTA VIRUS, USING β-L-2'-DEOXYNUCLEOSIDES
WO2006050489A3 (en) Methods of entrapping, inactivating, and removing viral infections by the administration of respiratory tract compositions
WO2006101538A3 (en) Andrographolide derivatives to treat viral infections
HUP0401818A2 (en) Method of treating hepatitis virus infection with a multiphasic interferon delivery profile
WO2001068116A3 (en) Immunostimulatory polynucleotide sequences for use in preventing and treating respiratory viral infections
WO2004011478A3 (en) Anti-viral 7-deaza d-nucleosides and uses thereof
WO2001068077A3 (en) Immunostimulatory polynucleotide sequences for use in preventing and treating viral infections
WO2004028471A3 (en) Influenza therapeutic
MXPA02012443A (en) 3 -PRODRUGS OF 2 -DEOXY-bgr;-L-NUCLEOSIDES.
DE60323077D1 (en) IMMOBILIZATION AND STABILIZATION OF VIRUSES
WO2022217155A3 (en) Thionucleosides as antiviral agents
WO2007057763A3 (en) Nitric oxide as an anti-viral agent, vaccine and vaccine adjuvant
WO2007025043A3 (en) Seven-membered ring nucleosides
WO2008024843A3 (en) Combination therapy method for treating hepatitis c virus infection and pharmaceutical compositions for use therein
EP0652011A4 (en) Prophylactic and remedy for viral diseases in respiratory tract.
WO2005007078A3 (en) Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (sars)
WO2007029041A3 (en) Interferon lambda therapy for treatment of respiratory diseases
MXPA05005203A (en) Vaccine against hcv.
NO20055512L (en) Therapy or prevention of respiratory viral infections with alpha-thymosin peptides
ATE442155T1 (en) PARAPOX VIRUSES IN COMBINATION WITH OTHER ANTIVIRAL AGENTS FOR THE TREATMENT OF HIV/AIDS
MX2023000242A (en) Reduction of viral infections.
WO2007057436A3 (en) Interferon in influenza
WO2003037265A3 (en) Method of treating viral infections

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480021166.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 171991

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2526428

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006514937

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004270102

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004776085

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004270102

Country of ref document: AU

Date of ref document: 20040521

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004270102

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004776085

Country of ref document: EP